@cvulsteke.bsky.social
The unjustified fear of erdafitinib induced central serous retinopathy - Annals of Oncology www.annalsofoncology.org/article/S092...
FGFR inhibitors are FDA/EMA approved in cholangiocarcinoma and urothelial carcinoma with specific FGFR alterations. We propose new guidelines to manage eye toxicity.
FGFR inhibitors are FDA/EMA approved in cholangiocarcinoma and urothelial carcinoma with specific FGFR alterations. We propose new guidelines to manage eye toxicity.
The unjustified fear of erdafitinib induced central serous retinopathy
FGFR inhibitors are targeted cancer therapies that block the activity of FGFRs — a
family of receptor tyrosine kinases (FGFR1–FGFR4) involved in cell growth, survival,
angiogenesis, and differentiatio...
www.annalsofoncology.org
April 15, 2025 at 6:39 AM
The unjustified fear of erdafitinib induced central serous retinopathy - Annals of Oncology www.annalsofoncology.org/article/S092...
FGFR inhibitors are FDA/EMA approved in cholangiocarcinoma and urothelial carcinoma with specific FGFR alterations. We propose new guidelines to manage eye toxicity.
FGFR inhibitors are FDA/EMA approved in cholangiocarcinoma and urothelial carcinoma with specific FGFR alterations. We propose new guidelines to manage eye toxicity.
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study: Future Oncology: Vol 0, No 0
February 4, 2025 at 4:28 PM
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study: Future Oncology: Vol 0, No 0
First-line len + pembro did not meet prespecified statistical criteria for PFS or OS versus chemotherapy in pMMR aEC. ascopubs.org/doi/10.1200/...
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial | Journal of Clinical Oncology
PURPOSELenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free
survival (PFS) and overall survival (OS) versus chemotherapy in previously treated
advanced or recurrent end...
ascopubs.org
November 28, 2024 at 5:41 PM
First-line len + pembro did not meet prespecified statistical criteria for PFS or OS versus chemotherapy in pMMR aEC. ascopubs.org/doi/10.1200/...
We published an exploratory analysis of our keynote 361 trial by choice of chemotherapy backbone! Looks in line with checkmate 901…but EV302 is the new first line regimen to beat. Enfortumab Vedotin plus Pembrolizumab www.sciencedirect.com/science/arti...
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study
KEYNOTE-361 evaluated first-line pembrolizumab with and without platinum-based chemotherapy versus chemotherapy alone in advanced or metastatic urothe…
www.sciencedirect.com
November 18, 2024 at 7:34 PM
We published an exploratory analysis of our keynote 361 trial by choice of chemotherapy backbone! Looks in line with checkmate 901…but EV302 is the new first line regimen to beat. Enfortumab Vedotin plus Pembrolizumab www.sciencedirect.com/science/arti...